Do immune checkpoint inhibitors need new studies methodology?

Ferrara, Roberto; Pilotto, Sara; Caccese, Mario; Grizzi, Giulia; Sperduti, Isabella; Giannarelli, Diana; Milella, Michele; Besse, Benjamin; Tortora, Giampaolo; Bria, Emilio

Ferrara, Roberto; Pilotto, Sara; Caccese, Mario; Grizzi, Giulia; Sperduti, Isabella; Giannarelli, Diana; Milella, Michele; Besse, Benjamin; Tortora, Giampaolo; Bria, Emilio.

Afiliação

Ferrara R; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Pilotto S; U.O.C. Oncology, University of Verona, Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Caccese M; U.O.C. Oncology, University of Verona, Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Grizzi G; U.O.C. Oncology, University of Verona, Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Sperduti I; Regina Elena National Cancer Institute, Roma, Italy.
Giannarelli D; Regina Elena National Cancer Institute, Roma, Italy.
Milella M; Regina Elena National Cancer Institute, Roma, Italy.
Besse B; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Tortora G; U.O.C. Oncology, University of Verona, Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Bria E; U.O.C. Oncology, University of Verona, Comprehensive Cancer Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

J Thorac Dis ; 10(Suppl 13): S1564-S1580, 2018 May.

Article em En | MEDLINE | ID: mdl-29951307

Palavras-chave

Immune checkpoint inhibitors (ICI); clinical trial design; long-term benefit; milestone; survival analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Thorac Dis Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google